3.8 Article

Nanoformulation strategies for the enhanced oral bioavailability of antiretroviral therapeutics

期刊

THERAPEUTIC DELIVERY
卷 6, 期 4, 页码 469-490

出版社

FUTURE SCI LTD
DOI: 10.4155/TDE.15.4

关键词

-

资金

  1. Merck
  2. ViiV
  3. AstraZeneca
  4. Pfizer
  5. Janssen
  6. EPSRC [EP/K002201/1, EP/G066272/1] Funding Source: UKRI
  7. MRC [G0800247] Funding Source: UKRI
  8. Engineering and Physical Sciences Research Council [EP/K002201/1, EP/G066272/1] Funding Source: researchfish
  9. Medical Research Council [G0800247] Funding Source: researchfish

向作者/读者索取更多资源

The oral delivery of drugs with poor aqueous solubility is challenging and often results in poor bioavailability. Various nanoformulation platforms have demonstrated improved oral bioavailability of a range of drugs for different indications. The focus of this review is to provide an overview of the application of nanomedicine to oral antiretroviral therapy and outline how the current short-falls of this life-long therapy may be resolved using nanotechnology. As well as highlighting the rationale for a nanomedicine-based approach, the review focuses on the various strategies used to enhance oral bioavailability and describes the mechanisms of particle absorption across the GI tract. The recent advances in the development of long-acting formulations for both HIV treatment and pre-exposure prophylaxis are also discussed.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

3.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据